生存素与细胞分裂周期相关蛋白5在胃癌及胃间质瘤中的表达及其临床意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (5932 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective： To detect the expression of survivin and cell division cycle associated protein 5 (CDCA5) in gastric cancer and gastric stromal tumor, and analyze the correlation between them and their value in the evaluation of clinicopathological parameters. Methods： Firstly, the expression and correlation of survivin coding gene, BIRC5 (baculoviral IAP repeat containing 5) and CDCA5 in gastric cancer were analyzed by GEPIA database. Immunohistochemistry was used to detect the expression of survivin and CDCA5 in 76 cases of gastric cancer and 63 cases of gastric stromal tumor. Spearman′s rank correlation test was used to analyze the correlation between survivin and CDCA5 and clinicopathological features of the patients. Then, PROMO database was used to predict transcription factors that may act on their promoters. Finally, the interaction between survivin and CDCA5 was predicted by HDOCK. Results： GEPIA database analysis showed that the expressions of BIRC5 mRNA and CDCA5 mRNA in gastric cancer tissues were significantly higher than those in normal gastric tissues (P<0.01), and the expressions of BIRC5 mRNA and CDCA5 mRNA in gastric cancer tissues were positively correlated (r=0.79, P<0.01). Immunohistochemical results showed that the expression levels of survivin and CDCA5 were significantly higher than those of the corresponding paracancerous/paratumoral tissues (P<0.001), and the expressions of both were positively correlated in gastric cancer and gastric stromal tumor tissues (rgastric cancer=0.410，rgastric stromal tumor=0.347，both P<0.05). In gastric cancer, survivin was positively correlated with tumor size, lymphatic vessel invasion and TNM stage (all P<0.05); CDCA5 expression was negatively correlated with tumor differentiation (P<0.05) and positively correlated with TNM stage (P<0.05); and the copositive expression was closely related to tumor size, tumor differentiation lymphatic vessel invasion and TNM stage (all P<005). In gastric stromal tumors, survivin was positively correlated with mitosis and National Institute of Health (NIH) risk stratifications (P<0.05); CDCA5 was positively correlated with tumor size and NIH risk stratifications (P<0.05); and the copositive expression was positively correlated with tumor size, mitosis and NIH risk stratifications (P<0.05). In addition, PROMO identified 13 transcription factors that might regulate CDCA5 and BIRC5 promoters simultaneously. And HDOCK predicted that there were multiple pairs of interactions between survivin and CDCA5. Conclusion： Under the co-action of multiple transcription factors, survivin and CDCA5 were up-regulated in gastric cancer and gastric stromal tumour with a positive correlation. Both were related to some clinicopathological parameters of gastric cancer and gastric stromal tumor, and the clinical value of combined detection is greater than that of individual molecular detection.

Key words：

Received: 28 August 2022

Fund:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	BAO Jie1
	GAO Xiaojiao2
	HAN Wei3
	WANG Qinghua1

Cite this article:

BAO Jie1,GAO Xiaojiao2,HAN Wei3等. Expression and clinical significance of survivin and cell division cycle associated protein 5 in gastric cancer and gastric stromal tumor[J]. Journal of Jiangsu University(Medicine Edition), 2024, 24(01): 11-18.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2024/V24/I01/11

［1］杜彩妨, 李慧, 王琳. 晚期胃癌中少见靶点的特征与治疗进展［J］. 临床肿瘤学杂志, 2021, 26(6): 569-574.

［2］余韬, 舒徐. 胃间质瘤预后相关因素的临床研究进展［J］. 临床荟萃, 2018, 33(11): 1008-1012.

［3］刘瑞瑞, 殷实, 丁西平. 胃黏膜上皮异型增生及胃癌中线粒体超微结构的变化［J］. 安徽卫生职业技术学院学报, 2018, 17(3): 25-26, 29.

［4］郭影, 员永生, 王甜甜. 胃肠道间质瘤的临床病理研究［J］. 海南医学, 2009, 20(5): 146-147, 143.

［5］方仕旭, 林彬, 王峰, 等. 胃间质瘤临床病理特征及预后分析［J］. 中国医药导报, 2019, 16(20): 125-128.

［6］王泽涛, 陈剑通, 尚国印. Ki67免疫组化染色指数与胃间质瘤临床病理特征及预后的关系［J］. 哈尔滨医科大学学报, 2019, 53(5): 513-516.

［7］苗瑞政, 李乐平, 王永康, 等. 基质金属蛋白酶在胃间质瘤中的表达及其临床意义［J］. 中华外科杂志, 2007, 45(17): 1196-1198.

［8］乔萍, 袁海峰. 替吉奥胶囊治疗对胃癌患者血清sICAM1、Survivin、CA199、CA724水平的影响［J］. 检验医学与临床, 2020, 17(23): 3488-3491.

［9］Yun S, Kim WK, Kwon Y, et al. Survivin is a novel transcription regulator of KIT and is downregulated by miRNA494 in gastrointestinal stromal tumors［J］. Int J Cancer, 2018, 142(10): 2080-2093.

［10］符白玉, 林怡, 徐琪, 等. 胃癌患者血清p53、PDCD5、survivin表达水平及其联合应用的价值［J］. 分子诊断与治疗杂志, 2021, 13(4): 615-618, 622.

［11］董金辉, 赵滢, 王强. survivin、ki67及p53在胃肠道间质瘤中的表达及相关性研究［J］. 山东医药, 2009, 49(36): 86-87.

［12］Wang GH, Yao L, Xu HW, et al. Identification of MXRA5 as a novel biomarker in colorectal cancer［J］. Oncol Lett, 2013, 5(2): 544-548.

［13］Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249.

［14］李昌荣, 李红浪. Survivin与胃癌相关性的研究进展［J］. 世界华人消化杂志, 2014, 22(33): 5079-5085.

［15］Kim WJ, Kim W, Bae JM, et al. Dehydroabietic acid is a novel survivin inhibitor for gastric cancer［J］. Plants (Basel), 2021, 10(6): 1047.

［16］张艳霞, 章培军, 闫燕艳, 等. Ki67、PCNA和Survivin在胃肠道间质瘤组织中的表达［J］. 山东大学学报(医学版), 2013, 51(1): 67-70.

［17］Baykara M, Akkus M, Yildiz R, et al. Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma［J］. Int Immunopharmacol, 2011, 11(12): 2227-2231.

［18］高鑫, 张淑芳. 细胞分裂周期相关蛋白促肿瘤作用的研究进展［J］. 解放军医学院学报, 2019, 40(9): 904-907.

［19］何佩东, 李子坚. CDCA5与肿瘤［J］. 国际肿瘤学杂志, 2021, 48(1): 41-44.

［20］Zhang Z, Shen M, Zhou G. Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1［J］. Biochem Biophys Res Commun, 2018, 496(2): 482-489.

［21］王志鹏, 李坚, 袁荣霞, 等. 血浆长链非编码RNA AFAP1AS1和SOX2OT的表达对非小细胞肺癌的诊断价值［J］. 江苏大学学报(医学版), 2020, 30(3): 253-257, 262.

［22］芮菲菲, 杜娟, 郝忠分, 等. 转录因子GATA结合蛋白3对哮喘易感基因ADAM33表达的影响［J］. 江苏大学学报(医学版), 2022, 32(2): 131-135.

［23］Jung M, Bui I, Bonavida B. Role of YY1 in the regulation of antiapoptotic gene products in drugresistant cancer cells［J］. Cancers (Basel), 2023, 15(17): 4267.